Skip to main content
NIH Clinical Center
  Home | Contact Us | Site Map | Search
About the Clinical Center
For Researchers and Physicians
Participate in Clinical Studies

This file is provided for reference purposes only. It was current when it was produced, but it is no longer maintained and may now be out of date. Persons with disabilities having difficulty accessing information may contact us for assistance. For reliable, current information on this and other health topics, we recommend consulting the NIH Clinical Center at http://www.cc.nih.gov/.
Back to: Clinical Center Home Page > For Researchers and Physicians > Lectures
 
Astute Clinician Lectures

The NIH Director's Fourth Astute Clinician Lecture 2001
Poster for the lecture "STI571: A Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia (CML), Validating the Promise of Molecularly Targeted Therapy"

Videocast of Lecture Real Player Icon

Dr. Brian J. Druker
Professor of Medicine, Division of Hematology and Medical Oncology; Director, Oregon Health Sciences University Cancer Institute Leukemia Center.

Wednesday, November 7, 2001
Masur Auditorium
Warren Grant Magnuson Clinical Center 3-4 pm

Chronic myelogenous leukemia (CML) will be addressed in the fourth annual Astute Clinician Lecture on Nov. 7 by Dr. Brian Druker, Professor of Medicine and the Director of the Leukemia Center of the Oregon Cancer Institute at Oregon Health and Science University.

The lecture is an NIH Director's Wednesday Afternoon Lecture Series event hosted by the Clinical Center.

About the Speaker
Dr. Druker was instrumental in the development of STI571 for the treatment of CML. In 1993, in collaboration with Novartis Pharmaceuticals, he initiated preclinical studies with STI571 and served as the principal investigator on the Phase I clinical trials of this agent.

A 1981 graduate of the University of California San Diego School of Medicine, Dr. Druker completed an internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis, Missouri. He then trained in Medical Oncology at Harvard's Dana-Farber Cancer Institute.

After completing clinical training, Dr. Druker began laboratory work studying the role of tyrosine kinases in cancer. As part of his laboratory work, he developed the 4G10 monoclonal anti-phosphotyrosine antibody. Since 1990, Dr. Druker's focus has been the Bcr-Abl oncogene and chronic myelogenous leukemia.

His role in the development and clinical application of STI571 has resulted in numerous awards, including the AACR-Richard and Hinda Rosenthal Award and the Warren Alpert Prize from Harvard Medical School. Dr. Druker has also received the John J. Kenney Award from the Leukemia and Lymphoma Society, the American Cancer Society Medal of Honor, and the Dameshak Prize from the American Society of Hematology.

The Astute Clinician Lecture was established through a gift from Haruko and Robert W. Miller, M.D. It honors a U.S. scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research.

The Astute Clinician Lecture is an NIH Director's Wednesday Afternoon Lecture Series event. It is hosted by the Clinical Center. For information and accommodations, contact Hilda Madine, 301-594-5595.


Past Astute Clinician Lectures

"The Patients Who Taught Me and Led to My Discoveries in Congenital Adrenal Hyperplasia,"
December 13, 2000 - Maria I. New, M.D.

"The Elucidation of Lyme Arthritis,"
November 3, 1999 - Brian Druker, M.D

"The Link Between Teratogenesis and Carcinogenesis: Lessons from the Wilms Tumor Model.,"
October 15, 1998 - Dr. J. Bruce Beckwith

NOTE: Video requires the free RealPlayer.

Page last updated: February 17, 2010


Archived Spiderweb The information on this page is archived and provided for reference purposes only.

National Institutes
of Health
  Department of Health
and Human Services
 
NIH Clinical Center National Institutes of Health